LeMaitre inventory slumps 16% amid Q3 miss, slashed outlook (NASDAQ:LMAT)

LeMaitre Vascular (NASDAQ:LMAT) inventory fell ~16% on Friday after Q3 outcomes missed estimates and the corporate lowered its This fall and FY22 outlook.

Q3 EPS declined -16.7% Y/Y to $0.25, whereas web gross sales grew ~1.7% Y/Y to $39.03M. Each metrics, nevertheless, missed analysts estimates.

The gross margin decreased to 64.2%, in comparison with 64.8% in Q3 2021. The corporate stated the robust greenback decreased the gross margin by 1.7% Y/Y.

Revenue from operations fell -32.2% Y/Y to $6.15M.

Complete working bills elevated 19.8% Y/Y to $18.92M, pushed by elevated headcount, together with a 28% bigger salesforce and MDR-related regulatory bills, LeMaitre famous.

Dividend: On Oct. 25, the board authorised a quarterly dividend of $0.125/share, which might be paid on Dec. 1, to shareholders of document on Nov. 17.

Outlook:

FY22: LeMaitre lowered its full yr gross sales forecast and now expects it to be between $160.5M and $162.9M (Mid:$161.7M, +5% Y/Y, +9% Organically), prior forecast vary supplied throughout Q2 outcomes was $162.7M to $165.3M (Mid:$164.0M, +6%, +10% Org.); Consensus income estimate for 2022 is $162.88M.

EPS Ex-Spec. Cost is now anticipated between $1.02 and $1.08 (Mid: $1.05, -16%), prior forecast vary $1.14 to $1.19 (Mid: $1.17, -7%); Consensus $1.01.

Full yr EPS steering is now between $0.91 – $0.97 (Mid: $0.94, -25%), prior outlook $0.99 to $1.05 (Mid: $1.02, -19%).

This fall: The corporate additionally minimize is This fall gross sales steering and now expects it to be between $39.8M and $42.2M (Mid: $41.0mm, +4%, +9% Org.), prior forecast vary was $41.2M to $43.2M (Mid: $42.2M, +7%, +11% Org.); Consensus income estimate for This fall is $41.52M.

EPS outlook is now between $0.24 and $0.29 (Mid: $0.26, -5%), prior outlook $0.29 to $0.35 (Mid: $0.32, +15%).